Molecular precision
for urothelial cancer.
A biomarker panel for muscle-invasive (MIBC) and non-muscle-invasive (NMIBC) bladder cancer — designed for early detection, treatment stratification and recurrence monitoring, on the same fast PCR platform.
Why bladder is on our roadmap.
Bladder cancer is among the most under-served indications in Indian oncology — high recurrence rates, invasive monitoring, and few molecular tools to guide treatment. ONCO X is building a urine- and blood-based panel that changes the surveillance calculus.
Same platform. Same lab economics. New indication.
What it will cover.
- FGFR3 hotspot mutations — erdafitinib eligibility
- TERT promoter mutations
- PIK3CA · RAS · TP53
- ERBB2 (HER2) amplification
- Panel design finalising with clinical partners
Be the first to know when it launches.
Register your interest and we'll reach out when the bladder cancer panel is ready for early-access sites.
Register interest